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Abstract
Background: The West Nile virus (WNV) nonstructural protein 1 (NS1) is an important antigenic protein that elicits
protective antibody responses in animals and can be used for the serological diagnosis of WNV infection. Although
previous work has demonstrated the vital role of WNV NS1-specific antibody responses, the specific epitopes in the
NS1 have not been identified.
Results: The present study describes the identification of two linear B-cell epitopes in WNV NS1 through screening a
phage-displayed random 12-mer peptide library with two monoclonal antibodies (mAbs) 3C7 and 4D1 that directed
against the NS1. The mAbs 3C7 and 4D1 recognized phages displaying peptides with the consensus motifs LTATTEK
and VVDGPETKEC, respectively. Exact sequences of both motifs were found in the NS1 (895LTATTEK901 and
925VVDGPETKEC934). Further identification of the displayed B cell epitopes were conducted using a set of truncated
peptides expressed as MBP fusion proteins. The data indicated that 896TATTEK901 and925VVDGPETKEC934 are minimal
determinants of the linear B cell epitopes recognized by the mAbs 3C7 and 4D1, respectively. Antibodies present in
the serum of WNV-positive horses recognized the minimal linear epitopes in Western blot analysis, indicating that the
two peptides are antigenic in horses during infection. Furthermore, we found that the epitope recognized by 3C7 is
conserved only among WNV strains, whereas the epitope recognized by 4D1 is a common motif shared among WNV
and other members of Japanese encephalitis virus (JEV) serocomplex.
Conclusions: We identified TATTEK and VVDGPETKEC as NS1-specific linear B-cell epitopes recognized by the mAbs
3C7 and 4D1, respectively. The knowledge and reagents generated in this study may have potential applications in
differential diagnosis and the development of epitope-based marker vaccines against WNV and other viruses of JEV
serocomplex.
Background
West Nile virus (WNV) is the etiological agent of West
Nile fever (WNF), an important mosquito-borne disease
widely prevalent in Africa, Europe, Russia, the Middle
East, India, Australia and also in North America since
1999 [1]. WNV has expanded its geographic range since
the first identification of WNV cases in the United States
in 1999, and only in 2010, 981 human cases of WNF
were reported in the United States [2]. WNV is serologi-
cally classified into the Japanese encephalitis virus (JEV)
serocomplex, including JEV, Saint-Louis encephalitis
virus (SLEV), Murray Valley fever virus (MVEV) and
Kunjin virus, all of which are responsible for severe ence-
phalitis in humans and related animals [3,4].
The 10.7-kilobase genome of WNV encodes a single
polyprotein, which is cleaved into three structural proteins
(C, prM/M, and E) and seven nonstructural proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B and NS5) by both virus-
and host-encoded proteases. The seven nonstructural pro-
teins (glycoprotein NS1 and NS2A, protease cofactor
NS2B, protease and helicase NS3, NS4A, NS4B and the
polymerase NS5) associate with viral RNA to form the
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replication complex [5]. NS1 is a 48-Kd glycoprotein con-
taining 12 invariant cysteine residues. The antigenic varia-
bility of the NS1 provides a useful mechanism to
differentiate closely related flaviviruses [6]. NS1 is also
inserted into the lumen of the endoplasmic reticulum via
a signal peptide that is cleaved cotranslationally by a cellu-
lar signalase to generate the mature N terminus of the
protein [7]. Within infected cells, NS1 is believed to func-
tion as a cofactor in viral RNA replication, and specific
amino acids substitutions in NS1 can attenuate viral RNA
accumulation [8].In vivo, highly circulating levels of the
Dengue virus (DENV) NS1 early in Dengue illness corre-
lated with the development of Dengue hemorrhagic fever
and other severely associated diseases [9].
The diagnosis of WNV and associated diseases has long
been a challenge, especially in the field of differential
diagnosis. Assays employing reverse transcription-poly-
merase chain reaction (RT-PCR) are able to differentiate
closely related viruses, but these assays can only be
applied to specimens containing circulating virus or viral
RNA. Serological tests for WNV infections mainly
include the neutralization test, the hemagglutination-
inhibiting test, the enzyme-linked immunosorbent assay
(ELISA) and the immunofluorescence assay (IFA) [10].
Among these tests, the neutralization test is recognized
as the “gold standard” and provides the highest specifi-
city. However, neutralization assay requires paired acute-
and convalescent-phase serum specimens, and involves
manipulation of live virus which requires a high level of
biocontainment. The use of the IFA as a diagnostic tool
is also limited by practical issues related to biosafety. The
ELISA has also been used to detect immunoglobulin M
(IgM) antibodies that specifically react with WNV anti-
gens. However, these tests may be confounded by the
potential cross-reactivity of antibodies with other mem-
bers of the JEV serocomplex or other flaviviruses [11-13],
especially in regions where several flaviviruses coexist
[14]. In 1995, Hall et al developed an assay in which anti-
bodies against immunodominant epitopes in NS1 of
MVEV and Kunjin viruses were used to define targets for
a blocking ELISA. This assay was used to detect virus-
specific antibodies in sentinel animal sera, and confirmed
that NS1 could be used as a target protein to differentiate
viruses in the JEV serocomplex [15]. In a recent study, an
epitope-blocking ELISA based on a WNV NS1-specific
mAb was established and used to differentiate WNV
from JEV infections in horses and to detect natural infec-
tions among vaccinated populations [16-19].
Phage display describes an in vitro selection technique
in which a peptide or protein is genetically fused to a
coat protein of a bacteriophage, resulting in displaying
of the fused peptide or protein on the exterior of the
phage virion. Phage display library can consist of either
a random peptide library or a gene-targeted library, and
thus provides a powerful and economic technique for
epitope identification. This technology can identify
amino acids in protein antigens which are critical for
antibody binding and, further, the definition of peptide
motifs that are both structural and functional mimo-
topes of both protein and non-protein antigens [20,21].
Several studies have reported the usefulness of phage-
display applications for mapping epitopes of flaviviruses
[22-25].
The aim of our study was to identify WNV-specific
and/or JEV serocomplex-specific B-cell epitopes in NS1
using phage display technology. The information pro-
vided by this study will facilitate the development of
diagnostic tools for the specific serological diagnosis of
WNV infection, and will contribute to the rational
design of vaccines by furthering understanding of the
antigenic structure of NS1.
Results
Production of recombinant NS1
Recombinant WNV NS1 was successfully expressed in
E. coli TB1 cells, predominantly as soluble protein,
after induction with isopropyl b-D-1-thiogalactopyra-
noside (IPTG). The recombinant protein was recog-
nized by WNV-positive equine serum in Western blot
(WB) (Figure 1, lane 1).
Production and characterization of NS1-specific mAbs
Purified protein was used to immunize BALB/c mice.
After cell fusion and screening, several hybridoma cell
lines were obtained which produced NS1-specific mAbs.
Among them two cell lines were selected for their stron-
gest reactivity against recombinant NS1 using indirect
ELISA (data not shown), WB (Figure 2a), and against
native NS1 in IFA using WNV antigen slides (Figure 2b).
Further characterization of the specificity of the two
mAbs by IFA, demonstrated that the mAb 3C7 reacted
with WNV, but did not react with JEV, DENV1-4, Yellow
fever virus (YFV) and Tick-borne encephalitis virus
(TBEV), whereas mAb 4D1 reacted with both WNV and
JEV, but did not react with other non-JEV serocomplex
flaviviruses (Figure 2b).
The subtypes of the two mAbs were determined using
the Mouse MonoAb-ID Kit (HRP) according to the
manufacturer’s instructions. It was shown that the heavy
chain of 3C7 and 4D1 was IgG1 and the light chain was
l type. Antibody titers of culture supernatants of the
two hybridoma cell lines and the ascites prepared with
them were measured by indirect ELISA. Antibody titers
of the culture supernatants of mAbs 3C7 and 4D1 were
1:256 and 1:512, respectively; and those of the ascites
were 1:512,000 and 1:1,024,000, respectively.
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Phage enrichment by biopanning
Preparations of mAbs 3C7 and 4D1 were purified to
>90% (as determined by SDS-PAGE) and used to define
peptide binding motifs by screening a phage-displayed
12-mer peptide library. A dramatic enrichment of 3C7
and 4D1 antibody-reactive phages was achieved with
three sequential rounds of biopanning. As a measure of
enrichment, we calculated output-to-input ratios follow-
ing each round of selection with each mAb. The output-
to-input ratio is defined as the percentage of plaque-
forming phages remaining after elution from the mAbs.
The output-to-input ratios of the three rounds of bio-
panning were 0.00016%, 0.023% and 0.88% for the mAb
3C7, and 0.00018%, 0.023% and 0.89% for the mAb 4D1,
indicating significant enrichment of antibody reactive
phage clones.
Epitope prediction
Phage ELISA results showed that the selected ten phage
clones for every mAb (C1-C10 for 3C7 and D1-D10 for
4D1) demonstrated specific reactivity (OD492 nm > 1.0)
in comparison to a negative control of irrelevant specific
mAb, the anti-porcine interferon-g (IFN-g mAb (OD492
nm < 0.20) (Figure 3). By sequencing to determine the
insert sequences, alignment indicated that six 3C7-reac-
tive clones (C1-6) displayed a consensus sequence of
LTATTEK. Similarly, four 4D1-reactive clones (D1-4)
revealed another consensus sequence of VVDGPETKEC.
These consensus sequence motifs are identical to WNV
Figure 1 WNV-positive equine sera recognize recombinant
NS1. Binding of antibodies from WNV-positive equine serum to
recombinant NS1 (lane 1) and MBP-tag (lane 2) by Western blot. M,
PageRuler™ Prestained Protein Ladder (Fermentas, Canada).
Figure 2 Reactivity of mAbs with recombinant NS1 and C6/36 cells infected with flaviviruses. (a) Western blot analysis of mAbs 3C7 (lanes
1, 2) and 4D1 (lanes 3, 4) against recombination NS1 (lane 1, 3) and MBP-tag (lane 2, 4). M, PageRuler™ Prestained Protein Ladder (Fermentas,
Canada). (b) Pattern of immunofluorescence produced by anti-NS1 mAbs on antigen slides which were prepared on porous slides using C6/36
cells infected with different flaviviruses. Panels 1-8: reactivity of mAb 3C7 with cells infected with WNV (panel 1), JEV (panel 2), DENV1 (panel 3),
DENV2 (panel 4), DENV3 (panel 5), DENV4 (panel 6), YFV (panel 7), and TBEV (panel 8). Panels 11-18: reactivity of mAb 4D1 with cells infected
with WNV (panel 11), JEV (panel 12), DENV1 (panel 13), DENV2 (panel 14), DENV3 (panel 15), DENV4 (panel 16), YFV (panel 17), and TBEV (panel
18). Panels 9 and 19 are positive controls which used WNV-positive mouse serum. Panels 10 and 20 are negative controls which used WNV-
negative mouse serum.
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NS1 sequences 895LTATTEK901 and 925VVDGPET-
KEC934, respectively (Figure 4).
Identification of the displayed epitopes by WB using
expressed polypeptides
For further epitope determination, a series of wild-type
and truncated peptides deriving from LTATTEK (3C7)
and VVDGPETKEC (4D1) were produced and subjected
to WB. Results were shown that MBP-Cp-1 (MBP-fused
polypeptide containing Cp-1 peptide: LTATTEK) and
MBP-Cp-2 (MBP-fused polypeptide containing Cp-2
peptide: TATTEK) were recognized by mAb 3C7, and
only MBP-Dp-1 (MBP-fused polypeptide containing Dp-
1 peptide: VVDGPETKEC) was recognized by mAb
4D1, whereas all other peptides were unable to react
with the respective mAb (Figure 5). These data define
TATTEK and VVDGPETKEC as the linear epitopes
recognized by 3C7 and 4D1, respectively.
Reactivity of WNV/JEV-positive sera with the identified
NS1 epitopes
Recombinant proteins containing the two epitopes
were recognized by WNV-positive equine serum in
WB (Figure 6a, b), whereas they were not recognized
by WNV-negative control equine serum (Figure 6c, d).
Further cross-reaction detection showed the polypep-
tide Dp-1 (VVDGPETKEC) could react with six JEV-
positive equine sera (Figure 6e), but Cp-2 (TATTEK)
was not recognized by any JEV-positive equine serum
(Figure 6f). This was further confirmed by ELISA (data
not shown). These data indicate that the two peptides
are antigenic in horses.
Sequence similarity and prediction of cross-reactivity
To assess the degree of conservation of the linear epi-
topes recognized by the 3C7 and 4D1 mAbs, we ana-
lyzed the NS1 amino acid sequences from WNV isolates
Figure 3 Monoclonal antibody recognition of clones selected from the phage displayed peptide library. Ten clones selected after three
rounds of biopanning from phage display peptide library were tested for binding to each respective mAb by phage ELISA. (a) C1-C10 for
binding to mAb 3C7; (b) D1-D10 for binding to mAb 4D1; in both cases, the anti-porcine IFN-g mAb served as negative control.
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including Kunjin virus strains, and other members of
the family Flaviviridae. Analysis of NS1 sequences from
18 different WNV isolates indicated that the 3C7 epi-
tope, TATTEK is highly conserved among WNV lineage
1 strains including Kunjin virus strains and WNV line-
age 5 strains (EU249803; Figure 7a). Limited amino acid
mutations were present in WNV lineage 2, 3 and 4
strains (Figure 7a). Notably, the sequence motif is not
conserved among other members of the family Flaviviri-
dae, including other viruses of the JEV serocomplex
(Figure 7a). We also performed sequence alignments for
the minimal linear epitope recognized by the 4D1 mAb.
The motif VVDGPETKEC was a common epitope of
JEV serocomplex members, including WNV, JEV,
MVEV and SLEV, but was absent of non-JEV serocom-
plex members of the family (Figure 7b).
Discussion
NS1 is an important non-structural protein of flavi-
viruses. The impact of NS1 activity on flavivirus RNA
replication, host recognition of virus-associated molecu-
lar patterns and anti-viral protective immunity has been
well documented [26-29], as it has the importance of
antibodies generated against NS1. Studies have demon-
strated that the passive administration of NS1-specific
mAbs or active immunization with the NS1 gene or
protein confers protection from lethal flavivirus chal-
lenge [30,31]. Such protective effect could even be
observed when using NS1 produced by E. coli [32,33].
These results demonstrate that immune responses speci-
fically directed against NS1 play important roles in con-
ferring immune protection during infection with
flaviviruses.
Figure 4 Alignment of 12-mer peptide sequences from ELISA-positive clones defined the linear epitopes for the mAbs 3C7 (a) and
4D1 (b). The peptides inserted from ten phage clones that reacted with the mAbs 3C7 and 4D1 were aligned. Conserved amino acid residues
are boxed and consensus sequence motifs were provided below the alignments. The matching sequences 895LTATTEK901 and 925VVDGPETKEC934
in WNV NS1 are provided at the bottom of alignment for comparison.
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MAbs with well-defined epitopes provide an experimen-
tal platform for studying antigen structure, and developing
diagnostic reagents and therapeutics for pathogen control
[34-38]. Precise analysis of the epitopes in NS1 is impor-
tant for understanding the mechanism of NS1-mediated
protection. In recent years, epitope-based marker vaccine
has increasingly received attentions. By inserting con-
firmed epitopes into a target protein to immunize animals,
diagnostic methods based on the detection of antibodies
generated against the inserted epitopes could be developed
to investigate whether the generation of detected antibody
was a result of vaccination or natural infection. NS1 is
antigenic and elicits the generation of protective antibo-
dies. Identifying linear epitopes in NS1 would contribute
to developing epitope markers and epitope-based marker
vaccines. There are a few reports of mapping epitopes in
NS1 of DENV [39-41], TBEV [29] and JEV [42]. In the
case of WNV, epitope mapping has been exclusively
focused on the viral envelope (E) glycoprotein [43,44]. To
our knowledge, there has been no report mapping
epitopes in the WNV NS1.
In our current study, a panel of NS1-specific mAbs
was produced using soluble recombinant NS1 expressed
in E. coli. Two of the strongest reactive mAbs were
selected for further characterization based on IFA
results. The mAb 3C7 only reacted with WNV while the
mAb 4D1 reacted with both WNV and JEV, but not
other non-JEV serocomplex flaviviruses, such as
DENV1-4, YFV and TBEV.
The epitopes recognized by the two mAbs were deter-
mined using phage display technology, which has been
demonstrated to be a powerful and high-throughput
tool for the rapid mapping of epitopes [21,22,25]. Two
consensus peptide sequences corresponding to896TAT-
TEK901 and925VVDGPETKEC934 were identified. These
peptides were also recognized by WNV-positive equine
serum, but not WNV-negative equine serum, indicating
that the identified epitopes are antigenic in the context
of bona fide WNV infection. Although, our laboratory
only has one WNV-positive equine serum sample from
CSIRO Australian Animal Health Laboratory, we tested
six JEV-positive equine sera for reactivity against the
identified linear epitopes. None of the JEV-positive
equine sera reacted with the 3C7 epitope, whereas the
4D1 epitope reacted with all JEV-positive equine sera by
WB. Importantly, sequence alignment confirmed our
experimental data, as the epitope recognized by 3C7 was
completely conserved among WNV lineages 1 (including
Kunjin strains) and 5, moderately conserved in WNV
lineages 2, 3 and 4, but not conserved in JEV. The
potential cross-reactivity of 3C7 with WNV lineages 2, 3
and 4, where the first position of the peptide was
mutated, needs to be determined. The 4D1 epitope is
conserved in JEV serocomplex members with the excep-
tion of one amino acid (amino acid position 926, V®I).
However, further evaluation revealed that the V®I
mutation does not affect the reactivity of 4D1 mAb
(data not shown).
Figure 5 Reactivity of the recombinant MBP-fusion proteins containing wild-type and truncated motifs with mAbs 3C7 (a) and 4D1
(b). M, PageRuler™ Prestained Protein Ladder (Fermentas, Canada). The MBP-fusion proteins including the polypeptides: MBP-Cp-1(LTATTEK);
MBP-Cp-2 (TATTEK); MBP-Cp-3(LTATTE); MBP-Cp-4(ATTEK); MBP-Cp-5(LTATT); MBP-Dp-1(VVDGPETKEC); MBP-Dp-2(VDGPETKEC); MBP-Dp-3
(VVDGPETKE); MBP-Dp-4(DGPETKEC); MBP-Dp-5(VVDGPETK); MBP-Dp-6(GPETKEC); MBP-Dp-7(VVDGPET).
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The high degree of antibody cross-reactivity generated
among animals infected with flaviviruses has been a diag-
nostic challenge, and this limitation is apparent for mem-
bers of JEV serocomplex when using the gold standard
neutralization test [12]. This is largely due to the presence
of highly conserved and immunodominant epitopes in the
viral E glycoprotein that are responsible for eliciting cross-
reactive serum antibodies after infection [44]. Thus, it is
remarkable that we have identified a WNV-specific epi-
tope in NS1 since such an epitope has great potential to
improve WNV serological diagnostic tests and contribute
to the development of epitope-based marker vaccines.
Conclusions
The TATTEK and VVDGPETKEC are WNV NS1 speci-
fic linear B-cell epitopes recognized by the mAbs 3C7
and 4D1, respectively. The knowledge and reagents gen-
erated in this study may have applications in the differen-
tial diagnosis of viral infection and in the development of
epitope-based marker vaccines against WNV and other
viruses of JEV serocomplex.
Methods
Cell lines, plasmids, sera and viruses
The myeloma cell line SP2/0 was cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Invitrogen) in humi-
dified 5% CO2 atmosphere at 37°C. All culture media
were supplemented with 10%, 56°C 30 min heat-inacti-
vated fetal bovine serum (GIBCO, Invitrogen) and anti-
biotics (0.1 mg ml-1 of streptomycin and 100 IU ml-1 of
penicillin). The plasmids containing the WNV NY99 gen-
ome (GenBank AY842931.3) and pMAL™-C2x (New
Figure 6 Reactivity of recombinant MBP-fusion proteins containing epitopes TATTEK (MBP-Cp-2) and VVDGPETKEC (MBP-Dp-1) with
WNV/JEV-positive equine serum by WB. MBP alone or MBP fused with the TATTEK (MBP-Cp-2) and VVDGPETKEC (MBP-Dp-1) peptides were
evaluated by WB for reactivity with antibodies in WNV/JEV-positive equine serum. MBP-fused proteins containing the two epitopes reacted with
WNV-positive equine serum (Fig. 6 a, b) and WNV-negative equine serum (Fig. 6 c, d). The polypeptide Dp-1 and Cp-2 reacted with six JEV-
positive equine sera, respectively (Fig. 6 e and f). M: PageRuler™ Prestained Protein Ladder (Fermentas, Canada).
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Figure 7 Alignment of the 3C7 and 4D1 linear epitopes with the NS1 sequence of WNV and other flaviviruses. A total of 18 WNV strains
(12 WNV lineage 1 strains including 3 Kunjin virus strains and other four lineages of WNV strains: lineage 2 (HM147822, HM147824, DQ318020),
lineage 3 (AY765264), lineage 4 (GQ851605) and lineage 5 (EU249803)) and 14 associated flavivirus virus strains were used in the analysis. The
sequence motif recognized by each mAb was boxed.
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England Biolabs, Inc., USA) were maintained in our
laboratory. WNV-positive/negative mouse sera were
obtained from Beijing Institute of Microbiology and Epi-
demiology, and the WNV-positive/negative equine sera
were acquired from the CSIRO Australian Animal Health
Laboratory (AAHL). The flaviviruses strains (DENV-1,
D1-ZJ-57; DENV-2, D2-43; DENV-3, D3-80-2; DENV-4,
D4-B5; JEV, SA-14-14-2, GenBank AF315119.1; TBEV,
Senzhang, GenBank AY182009.1; WNV, Chin-01, Gen-
Bank AY490240.2; and YFV, 17D/tiantan, GenBank
FJ654700.1) used in this study were obtained from Beijing
Institute of Microbiology and Epidemiology.
Expression of recombinant NS1
The full-length NS1 coding sequence was amplified using
the primers WNVNS1-EcoRI-2470F (5’-GTAGAATTC-
GACACTGGGTGTGCCATAG-3’) and WNVNS1-XhoI-
3526R (5’-TGACTCGAGCATTCACTTGTGACTGCAC-
3’). These primers were designed according to the
sequence of WNV NY99 strain (GenBank AY842931.3)
and contained EcoR I and Xho I sites (shown in italics) to
facilitate directional cloning into the pMAL™-C2x expres-
sion vector following amplification, agarose gel purifica-
tion and restriction enzyme digestion. The recombinant
plasmid was verified by restriction enzyme digestion and
DNA sequencing, then it was transformed into E. coli TB1
(Takara) cells for expression. After several hours of shak-
ing, when the optical density (OD600 nm) is up to
0.5~0.7, IPTG (Pharmacia Biosciences) was added to a
final concentration of 0.5 mM into Rich medium (per liter
include: 10 g tryptone, 5 g yeast extract, 5 g NaCl, 2 g glu-
cose, autoclave; add sterile ampicillin to 100 μg ml-1) and
a further 10 h incubation at 16°C in agitation was per-
formed. Then bacteria were pelleted at 9000 g for 10 min
at 4°C and lysed by sonication in Column Buffer (20 mM
Tris-HCl, 200 mM NaCl, 1 mM EDTA), sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
was carried out to analyze the maltose-binding protein
(MBP) tagged recombinant NS1, and the reactivity identi-
fied by WB using WNV-positive/negative equine serum.
For WB, briefly, pMAL-NS1 recombinant protein and
pMAL™-C2x expressed MBP-tag were subjected to elec-
trophoresis on 12% SDS-PAGE after reduction with
dithiothreitol (DTT) at 100°C for 5 min, then samples
were transferred to a nitrocellulose membrane, nonspecific
antibody binding sites were blocked with 5% skimmed
milk powder in PBST overnight at 4°C. The membrane
was incubated with WNV-positive/negative equine serum
as the primary antibody at a 1:100 dilution, after incuba-
tion, each was washed five times with PBST, then it was
treated with HRP-conjugated rabbit anti-equine secondary
antibodies (LICOR Biosciences). The color was developed
using 3,3’-diaminobenzidine tetrahydrochloride (DAB) and
stopped by rinsing in deionized water followed by drying
the membrane.
Preparation and identification of mAbs against NS1
Recombinant NS1 fused with MBP-tag was produced in
E. coli as soluble in the cell lysate following IPTG induc-
tion. For preparation of immunogen, the soluble NS1
was purified by Amylose Resin according to pMAL™
Protein Fusion and Purification System, Version 5.01
(New England Biolabs, Inc., USA). Purified NS1 was
used for immunization. Hybridoma cells secreting anti-
NS1 antibodies were generated according to standard
procedures [45]. Briefly, six-week-old female BALB/c
mice were immunized subcutaneously with purified NS1
emulsified with an equal volume of Freund’s complete
adjuvant (Sigma, St. Louis, MO, USA). Two booster
injections containing purified NS1 with equal volume of
Freund’s incomplete adjuvant were given at 2-week
intervals. The final immunization, purified NS1 without
adjuvant was given intraperitoneally. Three days after
the final dose, mice were euthanized and spleen cells
were harvested and fused with SP2/0 myeloma cells at
5-10:1 ratio using polyethylene glycol (PEG 4000,
Sigma). Hybridoma cells were seeded into 96-well plates
and selected in HAT medium (DMEM containing 20%
fetal bovine serum, 100 ug ml-1 streptomycin, 100 IU
ml-1 penicillin, 100 mM hypoxanthine, 16 mM thymi-
dine and 400 mM aminopterin), and after 5 days, the
medium was removed and replaced with fresh HT-
DMEM medium. After HAT/HT selection, culture
supernatants of surviving clones were screened for reac-
tivity and specificity by indirect ELISA, WB and IFA.
The ELISA was described previously [46]. Briefly,
microplates were sensitized at 4°C overnight with affi-
nity-purified WNV-NS1 antigen at 100 ng ml-1. The
sensitized plates were incubated with culture superna-
tants from hybridoma cells at 37°C for 1 h, with HRP-
conjugated goat anti-mouse secondary antibodies
(LICOR Biosciences) at a 1:4,000 dilution at 37°C for 1
h, followed by color development with substrate solution
containing o-phenylenediamine (OPD). WB was per-
formed as described above, but the primary antibodies
were the mAbs supernatant and HRP-conjugated goat
anti-mouse secondary antibodies were used.
The IFA results were supplied by Beijing Institute of
Microbiology and Epidemiology. WNV, JEV, DENV1-4,
YFV and TBEV antigen slides were prepared on porous
slides using WNV, JEV, DENV1-4, YFV and TBEV
infected and uninfected C6/36 cells. Cell suspensions were
dripped onto slides, fixed using acetone, air dried and
stored at -20°C. Next, anti-NS1 mAbs supernatant and
WNV-, JEV-, DENV1-4-, YFV- and TBEV-positive/nega-
tive mouse sera (working dilution was 1:100) (positive/
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negative control) were incubated on acetone-fixed antigen
slides for 2 h. A FITC-conjugated goat anti-mouse IgG
(Sigma, USA) was used as a secondary antibody at a 1:50
dilution, and slides were viewed at a magnification of ×40
on a fluorescence microscope (Leica, Germany) [47].
The positive cell clones were subcloned three times by
limiting dilution method. Selected clones were cultured
in the peritoneal cavities of pristane (Sigma, USA)-
primed BALB/c mice to obtain ascites.
The mAb titer was determined by indirect ELISA as
described above and Ig subtypes of them were deter-
mined using the Mouse MonoAb-ID Kit (HRP) (Invitro-
gen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. This test identified IgG1, IgG2a, IgG2b,
IgG3, IgA and IgM subtype classes, while  and l light
chains were determined using monospecific rabbit poly-
clonal antibodies (Pabs).
Determination of epitopes by phage-displayed random
peptide library
The Ph.D.-12™ Phage Display Peptide Library Kit was
purchased from New England BioLabs Inc.. The dodeca-
peptide library consists of 2.7 × 109 electroporated
sequences (1.5 × 1013 pfu ml-1). All mAbs were purified
from ascites of mice inoculated with the hybridoma cells
secreting antibody by affinity chromatography using rPro-
tein G (Sigma, USA) according to the manufacturer’s
instructions, and the concentration of purified antibody
was determined by the Bradford Protein Assay Kit (http://
www.beyotime.com/CompatibilityChartForBradfordKit.
Pdf).
Three successive rounds of biopanning were carried out
according to the manufacturer’s instruction manual.
Briefly, one well of a 96-well microtiter plate was coated
with 15 μg of purified mAb in coating buffer (0.1 M
NaHCO3, pH 8.6), followed by blocking with blocking buf-
fer (0.1 M NaHCO3, pH 8.6 and 5 mg ml
-1 BSA) for 2 h at
4°C. About 1.5 × 1011 pfu (4 × 1010 phages, 10 μl of the
original library) were added to the well and incubated for
1 h at room temperature by gentle shaking. Unbound
phages were removed by successive washings with TBS
buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl) contain-
ing gradually increased concentrations (0.1%, 0.3%, and
0.5%) of Tween-20, and bound phages were eluted with
elution buffer (0.2 M Glycine-HCl, pH 2.2) containing
1 mg ml-1 BSA. The eluted phages were amplified in
early-log E. coli ER2738 strain cells. After three rounds of
biopanning, ten individual phage clones were selected and
assayed for target binding by sandwich ELISA as described
by the manufacturer’s instructions. Briefly, 96-well micro-
titer plates were coated overnight with 2 μg of mAb or
irrelevant control mAb (anti-porcine IFN-g mAb, Sigma,
USA). After 2 h of blocking with blocking buffer at 4°C,
phage clones were added to the wells (2 × 1011 pfu in
100 μl per well) and incubated with agitation for 2 h at
room temperature. Bound phages were subjected to reac-
tion with HRP-conjugated anti-M13 antibody (Pharmacia,
USA) for 2 h at room temperature, followed by color
development with substrate solution containing o-phenyle-
nediamine (OPD).
The DNA inserts displayed by ELISA-positive phage
clones were sequenced with the 96 gIII sequencing primer:
5’-TGAGCGGATAACAATTTCAC-3’ as described by the
manufacturer’s instructions (New England BioLabs Inc.).
Identification of the displayed epitopes by WB using
expressed polypeptides
A series of complementary oligonucleotides (Table 1)
encoding for wild-type and truncated versions of the
motifs LTATTEK and VVDGPETKEC were synthesized,
annealed and cloned into the EcoR I/Sal I sites of the pro-
karyotic expression vector pMAL™-C2x (New England
Biolabs, Inc., USA), resulting in a group of recombinant
plasmids. The E. coli TB1 cells with the recombinant plas-
mids were induced by IPTG up to 0.5 mM to produce
recombinant MBP-fusion polypeptides, then identified the
serial of polypeptides expression by WB using anti-MBP-
tag mAb (New England Biolabs, Inc., USA). WB was per-
formed as described above.
Detection of the reactivity of the epitopes with WNV/JEV-
positive equine serum
To verify whether the epitopes could be detected by
WNV/JEV-positive serum, the polypeptides MBP-Cp-2
(MBP fusion containing peptide of Cp-2) and MBP-Dp-1
(MBP fusion containing peptide of Dp-1) were subjected
to reaction with WNV/JEV-positive equine serum by WB.
WB was performed as described above, but the primary
antibody was WNV/JEV-positive equine serum and HRP-
conjugated rabbit anti-equine secondary antibodies
(LICOR Biosciences) were used [47]. The same test was
also performed using WNV-negative equine serum.
Homology and cross-reactivity analysis
To investigate the homology of the two epitopes to
equivalent sequences of flaviviruses, alignments of
sequences from homologous regions of 18 WNV NS1
(including 3 Kunjin virus strains) were completed by using
the DNASTAR Lasergene program (Windows version;
DNASTAR Inc., Madison, WI). Alignment analysis was
also performed between the identified epitopes and other
associated flavivirus strains, including the members of JEV
serocomplex, and another three antigenically related flavi-
viruses, DENV (type 1-4), YFV and TBEV, the factors of
isolation time and geographical location of all strains were
considered.
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